In vivo pharmacodynamic imaging of proteasome inhibition

Molecular Imaging

Volumn 8, Issue 3, 2009, Pages 140-147

  Kung, Andrew L ^a   Kimbrel, Erin A ^b   Davis, Tina N ^b   Bradner, James E ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

26 S PROTEASOME; APOPTOTIC EFFECTS; BORTEZOMIB; CANCER CELLS; DYNAMIC RANGE; HYPOXIA-INDUCIBLE FACTOR 1; IN-VITRO; IN-VIVO; MEDICAL NEEDS; NON-INVASIVE IMAGING; ORNITHINE DECARBOXYLASE; PROTEASOME INHIBITORS; PROTEASOMES; PROTEOLYTIC ACTIVITIES; REPORTER PROTEIN; TUMOR MODELS;

OXYGEN;

VIDEODISKS;

ACYLTRANSFERASE; ATP DEPENDENT 26S PROTEASE; HIF1A PROTEIN, HUMAN; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LUCIFERASE; ORNITHINE DECARBOXYLASE; PHOTOPROTEIN; PROTEASOME; PROTEINASE INHIBITOR; PUROMYCIN N ACETYLTRANSFERASE; PUROMYCIN N-ACETYLTRANSFERASE;

ANIMAL; ARTICLE; CELL STRAIN HCT116; CHEMISTRY; DRUG ANTAGONISM; GENE VECTOR; GENETICS; HUMAN; LUMINESCENCE; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; REPORTER GENE; WHOLE BODY IMAGING;

ACETYLTRANSFERASES; ANIMALS; GENES, REPORTER; GENETIC VECTORS; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUCIFERASES; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; MICE; MICE, NUDE; ORNITHINE DECARBOXYLASE; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; WHOLE BODY IMAGING;

EID: 70349295346     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2009.00007     Document Type: Article

References (30)

1. Yew PR, Kirschner MW. Proteolysis and DNA replication: the CDC34 requirement in the Xenopus egg cell cycle. Science 1997; 277:1672-1676
2. Verma R, Feldman RM, Deshaies RJ. SIC1 is ubiquitinated in vitro by a pathway that requires CDC4, CDC34, and cyclin/CDK activities. Mol Biol Cell 1997;8:1427-1437
3. Lee JC, Peter ME. Regulation of apoptosis by ubiquitination. Immunol Rev 2003;193:39-47.
4. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000;14:65-77.
5. Miller CP, Ban K, Dujka ME, et al. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110:267-277
6. Chauhan D, Hideshima T, Mitsiades C, Richardson P, et al. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 2005;4:686-692
7. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3: 17-26.
8. Moore BS, Eustaquio AS, McGlinchey RP. Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol 2008; 12:434-440
9. US Food and Drug Administration, Center for Drug Evaluation and Research. Velcade (bortezomib) information. Available at: http://www.fda.gov/cder/drug/ infopage/velcade/default.htm (accessed October 1, 2008).
10. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008;14:1649-1657
11. Zhang M, Pickart CM, Coffino P. Determinants of proteasome recognition of ornithine decarboxylase, a ubiquitin-independent substrate. EMBO J 2003;22:1488-1496
12. Li X, Coffino P. Degradation of ornithine decarboxylase: exposure of the C-terminal target by a polyamine-inducible inhibitory protein. Mol Cell Biol 1993;13:2377-2383
13. Hoyt MA, Zhang M, Coffino P. Probing the ubiquitin/proteasome system with ornithine decarboxylase, a ubiquitin-independent substrate. Methods Enzymol 2005;398:399-413.
14. Stack JH, Whitney M, Rodems SM, Pollok BA. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 2000;18:1298-1302
15. Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004;3: 9-23.
16. Thompson JF, Hayes LS, Lloyd DB. Modulation of firefly luciferase stability and impact on studies of gene regulation. Gene 1991;103: 171-177
17. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
18. Mazure NM, Brahimi-Horn MC, Berta MA, et al. HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 2004; 68:971-980
19. Safran M, Kim WY, O'Connell F, et al. Mouse model for noninvasive imaging ofHIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 2006;103:105-110
20. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia- inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-7992
21. Harada H, Kizaka-Kondoh S, Itasaka S, et al. The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 2007;360:791-796
22. Arquier N, Vigne P, Duplan E, et al. Analysis of the hypoxia-sensing pathway in Drosophila melanogaster. Biochem J 2006;393:471-480
23. Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue- specific expression of transgenes delivered by lentiviral vectors. Science 2002;295:868-872
24. Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi- gene deficiency in vivo using a single 'self-cleaving' 2A peptide- based retroviral vector. Nat Biotechnol 2004;22:589-594
25. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 2004;10:6290S-5S.
26. Luker GD, Pica CM, Song J, et al. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 2003;9:969-973
27. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008;90:270-283
28. Sun Y. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003;2:623-629
29. Love KR, Catic A, Schlieker C, Ploegh HL. Mechanisms, biology and inhibitors ofdeubiquitinating enzymes. Nat Chem Biol 2007;3: 697-705.
30. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003;2:803-811